

1 **Transgenic mouse lines expressing the 3xFLAG-dCas9 protein for enChIP**
2 **analysis**

3
4 Toshitsugu Fujita, Fusako Kitaura, Asami Oji, Naoki Tanigawa, Miyuki Yuno, Masahito Ikawa,
5 Ichiro Taniuchi, and Hodaka Fujii*

6
7 Toshitsugu Fujita, Hodaka Fujii
8 Department of Biochemistry and Genome Biology, Hirosaki University Graduate School of
9 Medicine, Zaifu-cho 5, Hirosaki, Aomori 036-8562, Japan

10
11 Toshitsugu Fujita, Fusako Kitaura, Naoki Tanigawa, Miyuki Yuno, Hodaka Fujii
12 Chromatin Biochemistry Research Group, Combined Program on Microbiology and Immunology,
13 Research Institute for Microbial Diseases, Osaka University, Yamadaoka 3-1, Suita, Osaka
14 565-0871, Japan

15
16 Asami Oji, Masahito Ikawa
17 Genome Information Research Center and Department of Experimental Genome Research,
18 Research Institute for Microbial Diseases, Osaka University, Yamadaoka 3-1, Suita, Osaka
19 565-0871, Japan

20
21 Ichiro Taniuchi
22 Laboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences,
23 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa 230-0045, Japan

24

25 Short title: Transgenic mice expressing 3xFLAG-dCas9

26

27 Keywords: enChIP, dCas9, ChIP, chromatin immunoprecipitation, transgenic mouse

28

29 *Corresponding author

30 E-mail: hodaka@hirosaki-u.ac.jp

31 Department of Biochemistry and Genome Biology, Hirosaki University Graduate School of

32 Medicine, Zaifu-cho 5, Hirosaki, Aomori, 036-8562 Japan

33 **Abstract**

34
35 We developed the engineered DNA-binding molecule-mediated chromatin immunoprecipitation
36 (enChIP) technology to isolate specific genomic regions while retaining their molecular
37 interactions. In enChIP, the locus of interest is tagged with an engineered DNA-binding molecule,
38 such as a modified form of the clustered regularly interspaced short palindromic repeats
39 (CRISPR) system containing a guide RNA (gRNA) and a catalytically inactive form of Cas9
40 (dCas9). The locus is then affinity-purified to enable identification of associated molecules. In
41 this study, we generated transgenic mice expressing 3xFLAG-tagged *Streptococcus pyogenes*
42 dCas9 (3xFLAG-dCas9) and retrovirally transduced gRNA into primary CD4⁺ T cells from these
43 mice for enChIP. Using this approach, we achieved high yields of enChIP at the targeted genomic
44 region. Our novel transgenic mouse lines provide a valuable tool for enChIP analysis in primary
45 mouse cells.

46 **Introduction**

47 Identification of molecules associated with a genomic region of interest *in vivo* is an essential step
48 in understanding the regulatory mechanisms underlying that region's functions. To this end, we
49 previously developed engineered DNA-binding molecule-mediated chromatin
50 immunoprecipitation (enChIP) technology to isolate genomic regions of interest along with their
51 interacting molecules (Fujita *et al.* 2013; Fujita & Fujii 2013). In enChIP, the locus of interest is
52 tagged with engineered DNA-binding molecules, such as transcription activator-like (TAL)
53 proteins (Bogdanove & Voytas 2011) or a variant of the clustered regularly interspaced short
54 palindromic repeats (CRISPR) system (Harrison *et al.* 2014; Wright *et al.* 2016) containing a
55 guide RNA (gRNA) and a catalytically inactive form of Cas9 (dCas9). The tagged locus is then
56 affinity-purified to enable identification of associated molecules. Locus-tagging can be achieved
57 in cells by expressing engineered DNA-binding molecules (Fujita *et al.* 2013; Fujita & Fujii 2013,
58 2014b; Fujita *et al.* 2015; Fujita *et al.* 2016a; Fujita *et al.* 2017b), or *in vitro* using recombinant or
59 synthetic engineered DNA-binding molecules (Fujita & Fujii 2014a; Fujita *et al.* 2016b; Fujita *et*
60 *al.* 2017a) Combination of enChIP with mass spectrometry (MS), RNA sequencing, and
61 next-generation sequencing (NGS) enables identification of proteins (Fujita *et al.* 2013; Fujita &
62 Fujii 2013, 2014b), RNAs (Fujita *et al.* 2015), and other genomic regions (Fujita *et al.* 2017a;
63 Fujita *et al.* 2017b) that interact with specific loci of interest in a non-biased manner.

64
65 To perform locus-tagging in primary cells, it is necessary to express both dCas9 and gRNA by
66 transduction or other methods. However, the low transduction efficiency of some cell lineages
67 results in a low percentage of cells expressing both dCas9 and gRNA. To resolve this technical
68 issue, we generated transgenic (Tg) mouse lines expressing 3xFLAG-tagged *Streptococcus*

69 *pyogenes* dCas9 (3xFLAG-dCas9), either constitutively or inducibly. To facilitate their use in
70 various experimental contexts, expression of the tagged dCas9 and/or a reporter green fluorescent
71 protein (GFP) can be flexibly induced or abolished by Cre- or FLPe-mediated site-specific
72 recombination events that delete expression-modulating cassettes. We anticipate that these novel
73 Tg mouse lines will serve as a powerful tool for efficient enChIP analysis in primary cells.

74 **Results and Discussion**

75

76 **Generation of Tg mouse lines expressing 3xFLAG-dCas9**

77 To facilitate enChIP analysis using primary mouse cells, we generated two Tg mouse lines
78 expressing 3xFLAG-dCas9 (Fig. 1A, B). One line, 3xFLAG-dCas9-IRES-EGFP, harbors
79 3xFLAG-dCas9 and IRES-EGFP in the *Rosa26* locus (Fig. 1A). In the other line, 3xFLAG-dCas9
80 and IRES-EGFP are present at the *Rosa26* locus, but expression of 3xFLAG-dCas9 can be
81 induced by Cre-mediated deletion of the STOP cassette (along with the *neo^r* gene), and EGFP
82 expression can be disrupted by FRT-mediated deletion of the IRES-EGFP cassette (Fig. 1B (i)).
83 3xFLAG-dCas9/CTV (*neo⁺*/ *GFP⁺*) mice were crossed with CAG-Cre mice (Matsumura *et al.*
84 2004) to delete the STOP cassette and *neo^r* gene, yielding 3xFLAG-dCas9/CTV (*GFP⁺*) mice
85 (Fig. 1B (ii)). 3xFLAG-dCas9/CTV (*GFP⁺*) mice can be further crossed with CAG-FLPe mice
86 (Schaff *et al.* 2001) to delete the IRES-EGFP cassette, yielding 3xFLAG-dCas9/CTV mice (Fig.
87 1B (iii)). Targeted integration of transgenes was confirmed by PCR (Fig. 1C). All mice were
88 viable and fertile with normal litter sizes and did not exhibit any morphological abnormalities.
89 Expression of EGFP was observed throughout the body, including thymocytes and splenocytes
90 (Fig. 2A), and 3xFLAG-dCas9 was detected in nuclear extracts (NE) of thymocytes (Fig. 2B). In
91 conventional enChIP using primary cells from mice, it is necessary to transduce both tagged
92 dCas9 and gRNA. To compare the number of Tg mice required for enChIP with that required for
93 conventional enChIP, we isolated CD4⁺ T cells from a wild-type C57BL/6 mouse and transduced
94 them with a retroviral plasmid expressing 3xFLAG-dCas9 (3xFLAG-dCas9/MSCV-EGFP). As
95 shown in Supplementary Figure S1, the transduction efficiency of 3xFLAG-dCas9/MSCV-EGFP
96 was about 10%. Considering that all cells express 3xFLAG-dCas9 in our Tg mice (Fig. 2A), this

97 means that 10 times more mice are required for conventional enChIP than for enChIP using our
98 Tg mice. Thus, our Tg mouse lines have the advantage of reducing the number of mice required
99 for enChIP, as well the time and effort needed to perform enChIP analysis in primary mouse
100 cells.

101

102 **enChIP analysis using primary CD4⁺ T cells**

103 Next, we performed enChIP analysis using primary cells from the Tg mice (Fig. 3A). For these
104 experiments, CD4⁺ T cells were purified from 3xFLAG-dCas9-IRES-EGFP mice and
105 3xFLAG-dCas9/CTV (GFP⁺) mice and activated with anti-CD3 and anti-CD28 Abs. The
106 activated cells were transduced with a retroviral vector expressing gRNA targeting the *c-myc*
107 promoter (m-*c-myc* gRNA #1/pSIR-hCD2) or a negative control vector (pSIR-hCD2), and 2 days
108 later, hCD2⁺ cells were isolated and expanded in media containing IL-2. Cells were fixed with
109 formaldehyde and subjected to enChIP analysis using anti-FLAG Ab. Yields of enChIP were
110 monitored by real-time PCR. As shown in Figure 3B and C, efficient enrichment of the *c-myc*
111 promoter region, but not irrelevant loci (*Gapdh*, *Pax5*), was detected in samples expressing
112 gRNA targeting the *c-myc* locus. By contrast, no enrichment was observed for samples in the
113 absence of gRNA. The yields of enChIP were comparable between 3xFLAG-dCas9-IRES-EGFP
114 mice and 3xFLAG-dCas9/CTV (GFP⁺) mice. These results demonstrate that primary cells from
115 these Tg mice can be used for enChIP analysis.

116

117 **Conclusions**

118 We generated Tg mouse lines expressing 3xFLAG-tagged dCas9 and retrovirally transduced
119 gRNA targeting a genomic locus into primary CD4⁺ T cells from these mice. Using this approach,
120 high yields of enChIP could be achieved. Thus, these Tg mouse lines represent a useful tool for
121 enChIP analysis in primary mouse cells. The injection of adenovirus-mediated gRNA (Platt *et al.*
122 2014) into these Tg mice should also enable the isolation of genomic regions of interest from
123 mouse tissues without the need for primary cell cultures. In addition, the Tg mouse strains
124 generated in this study could be used for CRISPR interference (CRISPRi) experiments (Qi *et al.*
125 2013) using primary mouse cells. However, in enChIP analysis, such CRISPRi effects might be
126 problematic. Therefore, it would be better to choose gRNA target sequences that bind to the
127 CRISPR complex without interfering with the functions of the target genomic regions.

128 **Experimental procedures**

129

130 **Plasmids**

131 To construct pCAG1.2-PM, a modified pCAGGS plasmid (Niwa *et al.* 1991) was digested with
132 *SacI*. Two oligonucleotides, *MluI*-*PmeI* oligo-S (27551) and *MluI*-*PmeI* oligo-A (27552), were
133 annealed, phosphorylated, and inserted into the digested plasmid, yielding two plasmids,
134 pCAG1.2-PM (*PmeI*-*MluI*) and pCAG1.2-MP (*MluI*-*PmeI*), distinguished by the orientations of
135 the oligonucleotides. To construct 3xFLAG-dCas9/pCAG1.2-PM, pCAG1.2-PM was digested
136 with *EcoRV* and *NotI*. 3xFLAG-dCas9/pMXs-puro (Addgene #51240) was digested with *PacI*,
137 blunted, and further digested with *NotI*. The vector backbone and the coding sequence of
138 3xFLAG-dCas9 were purified by agarose gel electrophoresis and ligated. To construct
139 3xFLAG-dCas9-IG/pCAG1.2-PM, 3xFLAG-dCas9/pCAG1.2-PM and 3xFLAG-dCas9/pMXs-IG
140 (Addgene #51258) were digested with *NotI* and *SalI*, respectively. After blunting, the plasmids
141 were further digested with *AscI*. The vector backbone and the coding sequence of
142 3xFLAG-dCas9 were purified by agarose gel electrophoresis and ligated. To construct
143 3xFLAG-dCas9-IG/pSKII-ROSA, pSKII-ROSA26arm0.5kb-zeo was digested with *BamHI* and
144 *SalI*, and 3xFLAG-dCas9-IG/pCAG1.2-PM was digested with *MluI* and *PacI*. After blunting, the
145 vector backbone and the coding sequence of 3xFLAG-dCas9 were purified by agarose gel
146 electrophoresis and ligated.

147

148 To construct 3xFLAG-dCas9/CTV, CTV (Addgene #15912) was digested with *AscI*, and
149 3xFLAG-dCas9/pMXs-puro was digested with *PacI* and *NotI*. After blunting, the vector

150 backbone and the coding sequence of 3xFLAG-dCas9 were purified by agarose gel
151 electrophoresis and ligated.
152
153 To construct 3xFLAG-dCas9/MSCV-EGFP (Addgene #82613), the MSCV-EGFP plasmid
154 (DeKoter *et al.* 1998) was digested with *Hpa* I and ligated with the coding sequence of
155 3xFLAG-dCas9, which was derived from 3xFLAG-dCas9/pMXs-puro by digesting with *Pac* I
156 and *Not* I followed by blunting with DNA Blunting Kit (Takara).

157
158 To construct a gBlock targeting the mouse *c-myc* promoter, the oligonucleotides mcMYC
159 promoter 1 sense (27822) and mcMYC promoter 1 antisense (27823) were annealed,
160 phosphorylated, and inserted into gRNA cloning vector *Bbs*I ver. 1 digested with *Bbs*I. To
161 construct m-*c-myc* gRNA #1/pSIR, the gBlock was excised with *Xho*I and *Hind*III and inserted
162 into *Xho*I/*Hind*III-cleaved pSIR (Clontech). To construct a retroviral vector for expression of
163 gRNA against the mouse *c-myc* promoter (m-*c-myc* gRNA #1/pSIR-hCD2), pSIR-hCD2
164 (Addgene #51143) and m-*c-myc* gRNA #1/pSIR were digested with *San*DI and *Hind*III. The
165 vector backbone and insert were purified by agarose gel electrophoresis and ligated.

166

167 Oligonucleotides used for construction of plasmids are shown in Table 1.

168

169 **Mice**

170 Embryonic stem (ES) cells (EGR-101) (Fujihara *et al.* 2013) were transfected with linearized
171 3xFLAG-dCas9-IG/pSKII-ROSA, as described previously (Oji *et al.* 2016). ES cells retaining the
172 transgene in the *Rosa26* locus were injected into blastocysts (ICR × ICR) to generate chimeric
173 mice. The chimeric mice were crossed with B6D2F1 mice to generate heterozygous

174 3xFLAG-dCas9-IRES-EGFP mice (strain name:
175 B6D2-*Gt(ROSA)26Sor^{em1(CAG-3XFLAG-dCas9,-EGFP)Osb}*) (RIKEN BioResource Center RBRC09976;
176 Kumamoto University Center for Animal Resources and Development (CARD): CARD ID
177 2531).
178
179 B6JN/1 ES cells (Moriyama *et al.* 2014), derived from a hybrid between C57BL/6J and
180 C57BL/6N, were electroporated with 3xFLAG-dCas9/CTV plasmid linearized with *AsiSI*. To
181 generate chimeric mice, ES cells containing the *neo^r* gene, transgene, and *GFP* gene in the
182 *Rosa26* locus were injected into blastocysts (Balb/c × Balb/c) by the animal facility group at
183 RIKEN IMS. The chimeric mice were crossed with C57BL/6 mice to generate heterozygous
184 3xFLAG-dCas9/CTV (*neo⁺/GFP⁺*) mice (strain name:
185 C57BL/6-*Gt(ROSA)26Sor^{tm1(CAG-3XFLAG-dCas9,-EGFP)Hfuj}*). The 3xFLAG-dCas9/CTV (*neo⁺/GFP⁺*)
186 mice were crossed with CAG-Cre mice (Matsumura *et al.* 2004) to generate
187 3xFLAG-dCas9/CTV (*GFP⁺*) mice (strain name:
188 C57BL/6-*Gt(ROSA)26Sor^{tm1.1(CAG-3XFLAG-dCas9,-EGFP)Hfuj}*). The 3xFLAG-dCas9/CTV (*GFP⁺*) mice
189 can be crossed with CAG-FLPe mice (Schaff *et al.* 2001) to generate 3xFLAG-dCas9/CTV mice
190 (strain name: C57BL/6-*Gt(ROSA)26Sor^{tm1.2(CAG-3XFLAG-dCas9)Hfuj}*).

191
192 All animal experiments were approved by the Institutional Animal Care and Use Committee at
193 Research Institute for Microbial Diseases, Osaka University.

194

195 **Genotyping**

196 For genotyping, genomic DNA was extracted and subjected to PCR with KOD FX (Toyobo).
197 PCR conditions were as follows: heating at 94°C for 2 min; followed by 38 cycles of 98°C for 10
198 s, 62°C for 30 s, and 68°C for 4 min. Primers used for genotyping PCR are shown in Table 1.

199

200 **Cell staining and flow cytometry**

201 Thymi and spleens were isolated from euthanized mice and used to prepare single cells. For
202 surface staining, cells were stained for 30 minutes at 4°C with fluorochrome-conjugated
203 antibodies (Abs): fluorescein isothiocyanate (FITC)-conjugated mouse CD4 (130-102-541,
204 Miltenyi) and phycoerythrin (PE)-conjugated human CD2 (hCD2) (347597, BD Bioscience).
205 Flow cytometric analysis was performed on a FACSCalibur (BD Biosciences) and analyzed with
206 the FlowJo software (TreeStar).

207

208 **Immunoblot analysis**

209 NE were prepared with NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher
210 Scientific). Aliquots of NE (10 µg) were subjected to immunoblot analysis with anti-FLAG M2
211 Ab (F1804, Sigma-Aldrich), as described previously (Fujita & Fujii 2013).

212

213 **Transduction of gRNA and isolation of transduced cells**

214 Transduction of retroviral expression plasmids into primary CD4⁺ T cells was performed as
215 described previously (Naoe *et al.* 2007). Briefly, CD4⁺ T cells were purified from spleens using
216 the Mouse CD4⁺ T cell isolation kit (Miltenyi, 130-104-454). Purified CD4⁺ T cells were
217 activated with anti-CD3 Ab (3 µg/ml, 145-2C11, 553057, BD Pharmingen) and anti-CD28 Ab (3
218 µg/ml, 37.51, 553295, BD Pharmingen). A retroviral expression plasmid was transfected into
219 Plat-E cells (Morita *et al.* 2000) along with pPAM3 (Miller & Buttimore 1986) using

220 Lipofectamine 3000 (Invitrogen) to produce retroviral particles. Activated CD4⁺ T cells were
221 transduced with the retroviral particles by the spin infection method (Naoe *et al.* 2007). After
222 culturing for 2 days in RPMI complete media containing mouse IL-2 (20 ng/ml, 402-ML, R & D
223 Systems), transduced cells were analyzed by flow cytometry. hCD2⁺ cells were purified using
224 human CD2 MicroBeads (130-091-114, Miltenyi) and used for enChIP analysis.

225

226 **enChIP real-time PCR**

227 enChIP real-time PCR was performed as described previously (Fujita & Fujii 2013) with some
228 modifications. Briefly, the CD4⁺ T cells (ca. 1×10^6) were crosslinked with 0.1% formaldehyde
229 in RPMI complete media at 37°C for 10 min. After quenching and washing with PBS, the
230 chromatin fraction was extracted and fragmented by sonication. The sonicated chromatin was
231 used for enChIP using 2 µg of anti-FLAG M2 Ab. DNA was purified using CHIP DNA Clean &
232 Concentrator (Zymo Research) and subjected to real-time PCR. Primers used in the analysis are
233 shown in Table 1.

234 **Acknowledgments**

235 We thank S. Muroi for genotyping ES cells, T. Ishikura for injection of ES cells into blastocysts,
236 and K. Rajewsky and H. Singh for providing plasmids (Addgene plasmid # 15912 and
237 MSCV-EGFP, respectively).

238

239 **Funding**

240 This work was supported by the Takeda Science Foundation (T.F.), Grant-in-Aid for Scientific
241 Research (C) (#15K06895) (T.F.), and Grant-in-Aid for Scientific Research (B) (#15H04329) (T.F.,
242 H.F.), ‘Transcription Cycle’ (#15H01354) (H.F.) from the Ministry of Education, Culture, Sports,
243 Science and Technology of Japan.

244

245 **Abbreviations:** enChIP, engineered DNA-binding molecule-mediated chromatin
246 immunoprecipitation; CRISPR, clustered regularly interspaced short palindromic repeats; dCas9,
247 catalytically inactive form of Cas9; gRNA, guide RNA; GFP, green fluorescent protein; MS,
248 mass spectrometry; NGS, next-generation sequencing; Tg, transgenic.

249

250 **Conflicts of interests**

251 T.F. and H.F. have patents on enChIP (“Method for isolating specific genomic region using
252 molecule binding specifically to endogenous DNA sequence”; patent number: Japan 5,954,808;
253 patent application number: WO2014/125668). T.F. and H.F. are founders of Epigeneron, Inc.

254

255 **Availability of data and materials**

256 All data generated or analyzed during this study are included in the published article. Tg mice
257 generated in this study can be obtained from RIKEN BioResource Center and Kumamoto
258 University Center for Animal Resources and Development (CARD).

259

260 **Authors' contributions**

261 H.F. designed and performed experiments (design and construction of transgenes, flow
262 cytometric analysis, immunoblot analysis, transduction of retroviruses), wrote the manuscript,
263 and directed and supervised the study. T.F. and M.Y. performed enChIP analyses. N.T.
264 constructed the retrovirus vector expressing gRNA targeting the *c-myc* locus, and performed
265 transduction of gRNA retroviruses and enChIP analysis. F.K. and M.Y. maintained the mouse
266 colony. F.K. screened ES cells and genotyped mice. A.O. and M.I. performed CRISPR-mediated
267 knock-in of 3xFLAG-dCas9-IRES-EGFP transgenes. I.T. generated ES cells harboring the
268 3xFLAG-dCas9/CTV transgene, chimeric mice, and knock-in mice.

269 **References**

- 270 Bogdanove, A.J. & Voytas, D.F. (2011) TAL effectors: customizable proteins for DNA targeting.
271 *Science* **333**, 1843-1846.
- 272 DeKoter, R.P., Walsh, J.C. & Singh, H. (1998) PU.1 regulates both cytokine-dependent
273 proliferation and differentiation of granulocyte/macrophage progenitors. *EMBO J.* **17**, 4456-4468.
- 274 Fujihara, Y., Kaseda, K., Inoue, N., Ikawa, M. & Okabe, M. (2013) Production of mouse pups
275 from germline transmission-failed knockout chimeras. *Transgenic Res.* **22**, 195-200.
- 276 Fujita, T., Asano, Y., Ohtsuka, J., Takada, Y., Saito, K., Ohki, R. & Fujii, H. (2013)
277 Identification of telomere-associated molecules by engineered DNA-binding molecule-mediated
278 chromatin immunoprecipitation (enChIP). *Sci. Rep.* **3**, 3171.
- 279 Fujita, T. & Fujii, H. (2013) Efficient isolation of specific genomic regions and identification of
280 associated proteins by engineered DNA-binding molecule-mediated chromatin
281 immunoprecipitation (enChIP) using CRISPR. *Biochem. Biophys. Res. Commun.* **439**, 132-136.
- 282 Fujita, T. & Fujii, H. (2014a) Efficient isolation of specific genomic regions retaining molecular
283 interactions by the iChIP system using recombinant exogenous DNA-binding proteins. *BMC Mol.*
284 *Biol.* **15**, 26.
- 285 Fujita, T. & Fujii, H. (2014b) Identification of proteins interacting with genomic regions of
286 interest in vivo using engineered DNA-binding molecule-mediated chromatin
287 immunoprecipitation (enChIP). *Bio-Protoc.* **4**, e1124.
- 288 Fujita, T., Kitaura, F., Yuno, M., Suzuki, Y., Sugano, S. & Fujii, H. (2017a) Locus-specific ChIP
289 combined with NGS analysis reveals genomic regulatory regions that physically interact with the
290 Pax5 promoter in a chicken B cell line. *DNA Res.* **24**, 537-548.
- 291 Fujita, T., Yuno, M. & Fujii, H. (2016a) Allele-specific locus binding and genome editing by
292 CRISPR at the p16INK4a locus. *Sci. Rep.* **6**, 30485.

- 293 Fujita, T., Yuno, M. & Fujii, H. (2016b) Efficient sequence-specific isolation of DNA fragments
294 and chromatin by in vitro enChIP technology using recombinant CRISPR ribonucleoproteins.
295 *Genes Cells* **21**, 370-377.
- 296 Fujita, T., Yuno, M., Okuzaki, D., Ohki, R. & Fujii, H. (2015) Identification of non-coding RNAs
297 associated with telomeres using a combination of enChIP and RNA sequencing. *PLoS One* **10**,
298 e0123387.
- 299 Fujita, T., Yuno, M., Suzuki, Y., Sugano, S. & Fujii, H. (2017b) Identification of physical
300 interactions between genomic regions by enChIP-Seq. *Genes Cells* **22**, 506-520.
- 301 Harrison, M.M., Jenkins, B.V., O'Connor-Giles, K.M. & Wildonger, J. (2014) A CRISPR view of
302 development. *Genes Dev.* **28**, 1859-1872.
- 303 Matsumura, H., Hasuwa, H., Inoue, N., Ikawa, M. & Okabe, M. (2004) Lineage-specific cell
304 disruption in living mice by Cre-mediated expression of diphtheria toxin A chain. *Biochem.*
305 *Biophys. Res. Commun.* **321**, 275-279.
- 306 Miller, A.D. & Buttimore, C. (1986) Redesign of retrovirus packaging cell lines to avoid
307 recombination leading to helper virus production. *Mol Cell Biol.* **6**, 2895-2902.
- 308 Morita, S., Kojima, T. & Kitamura, T. (2000) Plat-E: an efficient and stable system for transient
309 packaging of retroviruses. *Gene Ther.* **7**, 1063-1066.
- 310 Moriyama, S., Takahashi, N., Green, J., Hori, S., Kubo, M., Cyster, J. & Okada, T. (2014)
311 Sphingosine-1-phosphate receptor 2 is critical for follicular helper T cell retention in germinal
312 centers. *J. Exp. Med.* **211**, 1297-1305.
- 313 Naoe, Y., Setoguchi, R., Akiyama, K., Muroi, S., Kuroda, M., Hatam, F., Littman, D. & Taniuchi,
314 I. (2007) Repression of interleukin-4 in T helper type 1 cells by Runx/Cbf beta binding to the Il4
315 silencer. *J. Exp. Med.* **204**, 1749-1755.

316 Niwa, H., Yamamura, K. & Miyazaki, J. (1991) Efficient selection for high-expression
317 transfectants with a novel eukaryotic vector. *Gene* **108**, 193-199.

318 Oji, A., Noda, T., Fujihara, Y., Miyata, H., Kim, Y., Muto, M., Nozawa, K., Matsumura, T.,
319 Isotani, A. & Ikawa, M. (2016) CRISPR/Cas9 mediated genome editing in ES cells and its
320 application for chimeric analysis in mice. *Sci. Rep.* **6**, 31666.

321 Platt, R.J., Chen, S., Zhou, Y. *et al.* (2014) CRISPR-Cas9 knockin mice for genome editing and
322 cancer modeling. *Cell* **159**, 440-455.

323 Qi, L.S., Larson, M.H., Gilbert, L.A., Doudna, J.A., Weissman, J.S., Arkin, A.P. & Lim, W.A.
324 (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene
325 expression. *Cell* **152**, 1173-1183.

326 Schaft, J., Ashery-Padan, R., van der Hoeven, F., Gruss, P. & Stewart, A. (2001) Efficient FLP
327 recombination in mouse ES cells and oocytes. *Genesis* **31**, 6-10.

328 Wright, A.V., Nuñez, J.K. & Doudna, J.A. (2016) Biology and Applications of CRISPR Systems:
329 Harnessing Nature's Toolbox for Genome Engineering. *Cell* **164**, 29-44.

330

331 **Figure legends**

332

333 **Fig. 1.** Generation of Tg mouse lines expressing 3xFLAG-dCas9. (A) Scheme of the targeted
334 locus of 3xFLAG-dCas9-IRES-EGFP. (B) Scheme of the targeted loci of (i)
335 3xFLAG-dCas9/CTV (neo^+/GFP^+); (ii) 3xFLAG-dCas9/CTV (GFP^+); and (iii)
336 3xFLAG-dCas9/CTV. (C) Genotyping PCR of Tg mouse lines.

337

338 **Fig. 2.** Expression of 3xFLAG-dCas9. (A) Expression of GFP in thymocytes and splenocytes
339 from Tg mice. Fluorescence in the FL-1 channel (GFP) is shown for C57BL/6 mice (WT: black)
340 and Tg mice (Tg: green). Numbers represent mean fluorescence intensities (MFI) in the FL-1
341 channel. (B) Expression of 3xFLAG-dCas9 in thymocytes from Tg mice. Expression of
342 3xFLAG-dCas9 was detected by immunoblot analysis with anti-FLAG Ab. Coomassie Brilliant
343 Blue (CBB) staining is shown as a protein loading control.

344

345 **Fig. 3.** enChIP analysis of $CD4^+$ T cells from 3xFLAG-dCas9 Tg mice. (A) Scheme of enChIP
346 analysis using Tg mouse lines. (B) Positions of primer sets used for enChIP real-time PCR. Green
347 letters: primer positions for c-myc (1); red letters: primer positions for c-myc (2); yellow
348 highlight: gRNA target site; underline: PAM. (C) Yields of enChIP analysis for the target site.
349 Error bars represent differences between duplicate analyses. N.D.: not detected. Irrelevant loci
350 (*Gapdh* and *Pax5*) were analysed as negative control loci.

351 **TABLE**

352

353 **Table 1. Oligodeoxyribonucleotides used in this study**


Number	Name	Sequence (5' → 3')	Experiments
27551	<i>MluI</i> - <i>PmeI</i> oligo-S	cacgcgtgtttaacgagct	Construction of pCAG1.2-PM and pCAG1.2-MP
27552	<i>MluI</i> - <i>PmeI</i> oligo-A	cgtttaaacacgcgtgagct	Construction of pCAG1.2-PM and pCAG1.2-MP
27699	ROSA-5' TF2	ctcagagagcctcggctagg	Genotyping of all Tg mouse lines
27644	Cas9-R	cagggcgataagattaccaaac	Genotyping of 3xFLAG-dCas9-IRES-EGFP
26013	oIMR0013	ctgggtggagaggctattc	Genotyping of 3xFLAG-dCas9/CTV (<i>neo</i> ⁺ / <i>GFP</i> ⁺)
28110	Cas9-R 27643	gtaggctttctgcctcctcact	Genotyping of 3xFLAG-dCas9/CTV (<i>neo</i> ⁺ / <i>GFP</i> ⁺) and 3xFLAG-dCas9/CTV (<i>GFP</i> ⁺)
27822	mcMYC promoter 1 sense	caccgcgccccgggacgtgcgtgacg	Construction of gRNA targeting <i>c-myc</i> promoter: sense strand
27823	mcMYC promoter 1 antisense	aaaccgtcacgcacgtccccgggcgc	Construction of gRNA targeting <i>c-myc</i> promoter: antisense strand
28157	mcMYC-0.62k-F	tatacgtggcagtgagttgctga	enChIP real-time PCR [<i>c-myc</i> (1)]
28158	mcMYC-0.44k-R	ctctaaggctggggaaaacagaa	enChIP real-time PCR [<i>c-myc</i> (1)]
28222	mc-myc_-0.1k-F	ctgaggctcctcctcctcttc	enChIP real-time PCR [<i>c-myc</i> (2)]
28223	mc-myc_-0.1k-R	cccttccccacctctctctattt	enChIP real-time PCR [<i>c-myc</i> (2)]
26574	mGAPDH-prom-F	gggttctataataacggactgc	enChIP real-time PCR (<i>Gapdh</i>)
26575	mGAPDH-prom-R	agcatcctagaccgtacagt	enChIP real-time PCR (<i>Gapdh</i>)
28091	mPax5-ChIP-prom-F	gacctatggaggttgcaattgag	enChIP real-time PCR (<i>Pax5</i>)
28092	mPax5-ChIP-prom-R	agcaagtgttttgaaccctgta	enChIP real-time PCR (<i>Pax5</i>)

354

355


A

bioRxiv preprint doi: <https://doi.org/10.1101/221820>; this version posted January 18, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.




B


(i) 3xFLAG-dCas9/CTV (*neo*⁺/*GFP*⁺)



(ii) 3xFLAG-dCas9/CTV (*GFP*⁺)





(iii) 3xFLAG-dCas9/CTV





C



(a) ROSA-5' TF2 (27699) x Cas9-R (27644)



(b) ROSA-5' TF2 (27699) x oIMR0013 (26013)



(c) ROSA-5' TF2 (27699) x Cas9-R 27643 (28110)



lanes

1, 3, 6: C57BL/6

2: 3xFLAG-dCas9-IRES-EGFP

4, 7: 3xFLAG-dCas9/CTV (*neo*⁺/*GFP*⁺)

5, 8: 3xFLAG-dCas9/CTV (*GFP*⁺)




Figure 2

bioRxiv preprint doi: <https://doi.org/10.1101/221820>; this version posted January 18, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.





Figure 3

bioRxiv preprint doi: <https://doi.org/10.1101/221820>; this version posted January 18, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

